PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128024
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128024
Cardiac Troponin Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of cardiac troponin Market
The global cardiac troponin market was valued at USD 3.50 billion in 2025 and is projected to grow from USD 3.78 billion in 2026 to USD 7.17 billion by 2034, exhibiting a CAGR of 8.30% during the forecast period. North America dominated the global cardiac troponin market with a 41.15% market share in 2025, supported by the widespread adoption of advanced cardiac diagnostics, increasing cardiovascular disease prevalence, and favorable reimbursement policies.
Cardiac troponin is the gold-standard biomarker used to detect cardiac muscle injury, particularly myocardial infarction (heart attack). Troponin I (cTnI) and Troponin T (cTnT) are highly specific proteins released into the bloodstream following damage to heart muscle cells. Rapid and accurate measurement of these biomarkers enables physicians to diagnose acute coronary syndrome (ACS) at an early stage, allowing timely treatment and improving patient outcomes. The growing burden of cardiovascular diseases, increasing geriatric population, technological advancements in high-sensitivity assays, and expanding adoption of point-of-care testing continue to drive market growth worldwide.
Rising Cardiovascular Disease Burden Drives Market Expansion
The increasing incidence of cardiovascular disorders remains the primary growth driver for the cardiac troponin market. Heart attacks, coronary artery disease, congestive heart failure, and acute coronary syndrome continue to increase globally due to aging populations, sedentary lifestyles, obesity, diabetes, and hypertension.
According to public health statistics, heart disease remains one of the leading causes of mortality worldwide, significantly increasing demand for rapid diagnostic biomarkers. High-sensitivity cardiac troponin assays have transformed emergency cardiac diagnosis by enabling clinicians to detect even minor myocardial injury within a few hours of symptom onset.
Additionally, the growing adoption of point-of-care (POC) diagnostic systems in emergency departments allows healthcare professionals to obtain faster results, improving treatment decisions and reducing hospital admission times.
Market Trends
One of the most important trends shaping the market is the increasing adoption of high-sensitivity cardiac troponin (hs-cTn) assays and point-of-care testing. These technologies provide faster, more accurate detection of myocardial injury compared to conventional laboratory assays.
Healthcare providers are increasingly integrating portable diagnostic devices into emergency rooms, ambulances, and remote healthcare facilities. Continuous product innovation, improved analytical sensitivity, AI-assisted interpretation, and automation are further strengthening the role of cardiac troponin testing in cardiovascular disease management.
Market Drivers
The growing prevalence of cardiovascular diseases continues to create strong demand for cardiac biomarker testing. Early diagnosis remains essential for reducing mortality associated with myocardial infarction and acute coronary syndrome.
Another major growth factor is the continuous introduction of technologically advanced diagnostic products by leading manufacturers. Companies are developing high-sensitivity assays capable of detecting extremely low concentrations of troponin with greater precision, enabling earlier intervention and improved patient outcomes.
Furthermore, the expanding elderly population is expected to significantly increase the number of cardiovascular diagnostic procedures over the coming years, creating sustained demand for cardiac troponin testing.
Market Restraints
Despite strong growth prospects, certain limitations continue to affect market expansion. Conventional cardiac troponin assays often lack sufficient sensitivity during the very early hours following myocardial infarction, limiting their diagnostic accuracy.
Although high-sensitivity assays have addressed many of these concerns, the transition from conventional testing systems requires substantial investment in laboratory infrastructure, equipment upgrades, and healthcare professional training, particularly in developing economies.
Market Opportunities
Growing investments in healthcare infrastructure, expanding emergency diagnostic services, and increasing availability of portable point-of-care testing systems present significant opportunities for market players.
Emerging economies across Asia Pacific, Latin America, and the Middle East are witnessing increasing healthcare modernization, providing manufacturers with opportunities to expand their product portfolios and strengthen distribution networks.
Furthermore, continuous research focused on improving biomarker sensitivity and integrating artificial intelligence into diagnostic platforms is expected to unlock new growth opportunities throughout the forecast period.
Segment Analysis
By Type
The Troponin I segment is projected to dominate the global market with a 73.32% market share in 2026. Troponin I remains the preferred biomarker due to its high specificity for myocardial infarction and growing availability of advanced high-sensitivity and point-of-care testing systems.
Meanwhile, the Troponin T segment is expected to witness strong growth, supported by increasing regulatory approvals, broader clinical adoption, and expanding use in early heart failure diagnosis.
By Setting
The laboratory testing segment is expected to account for 73.68% of the global market in 2026 owing to its superior analytical precision and widespread use in hospital laboratories.
The point-of-care testing segment is anticipated to record the fastest growth during the forecast period due to increasing use in emergency departments, ambulances, and resource-limited healthcare settings where rapid diagnosis is essential.
By Indication
The acute coronary syndrome (ACS) segment is expected to dominate the market with a 55.15% share in 2026. Rising cases of ACS worldwide continue to drive demand for rapid troponin testing for emergency diagnosis and patient triage.
Myocardial infarction remains another major application area, supported by the growing elderly population and increasing prevalence of heart attacks globally.
By End User
The hospitals & clinics segment is projected to hold the largest 63.44% market share in 2026. High patient admissions, increasing cardiovascular emergencies, and widespread adoption of advanced diagnostic assays contribute to segment dominance.
Diagnostic laboratories are also expected to witness healthy growth due to increasing outsourcing of cardiac testing services and expanding laboratory infrastructure.
Regional Analysis
North America dominated the global market with a value of USD 1.44 billion in 2025 and is projected to reach USD 1.56 billion in 2026. Strong healthcare infrastructure, rising cardiovascular disease prevalence, favorable reimbursement systems, and rapid adoption of high-sensitivity assays continue to drive regional growth. The U.S. market is projected to reach USD 1.40 billion in 2026.
Europe accounted for USD 0.92 billion in 2025 and is expected to reach USD 0.99 billion in 2026. Broad adoption of CE-marked diagnostic products, presence of major manufacturers, and increasing use of high-sensitivity assays support regional expansion.
Asia Pacific generated USD 0.74 billion in 2025 and is projected to grow to USD 0.80 billion in 2026, making it the fastest-growing regional market. Increasing cardiovascular disease burden, expanding healthcare infrastructure, growing awareness, and new product launches continue to fuel market growth across China, Japan, and India.
Latin America and the Middle East & Africa are also experiencing steady growth due to improving healthcare facilities, expanding diagnostic capabilities, and increasing government investments in cardiovascular disease management.
Competitive Landscape
The global cardiac troponin market remains moderately competitive, with several multinational diagnostic companies investing heavily in product innovation, regulatory approvals, and strategic collaborations.
Leading market participants include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers AG, bioMerieux SA, Beckman Coulter, QuidelOrtho, Eurolyser Diagnostica GmbH, PerkinElmer Inc., RESPONSE BIOMEDICAL, and LifeSign LLC.
Recent industry developments include new high-sensitivity assays, quality control solutions, innovative antibodies for immunoassays, and expanded regulatory approvals designed to improve diagnostic performance and strengthen competitive positioning.
Conclusion
The global cardiac troponin market is expected to experience robust growth through 2034, driven by the rising prevalence of cardiovascular diseases, increasing adoption of high-sensitivity diagnostic assays, and expanding use of point-of-care testing in emergency medicine. Technological advancements, continuous product innovation, and growing healthcare investments are improving diagnostic accuracy and patient outcomes worldwide. Although conventional assay limitations and infrastructure costs remain challenges, increasing awareness of early cardiac diagnosis, expanding healthcare access, and ongoing innovations in biomarker technology are expected to sustain long-term market growth.
Segmentation
By Type
- Troponin T
- Troponin I
By Setting
- Laboratory Testing
- Point-of-Care (POC) Testing
By Indication
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Others
By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Homecare Settings & Others
By Region
- North America ( By Type, By Setting, By Indication, By End User, By Country)
- U.S.
- Canada
- Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
- 4.2. Technological Advancements in Cardiac Troponin Testing
- 4.3. New Product Launches. By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
- 4.5. Impact of COVID-19 on the Market
5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Troponin T
- 5.1.2. Troponin I
- 5.2. Market Analysis, Insights and Forecast - By Setting
- 5.2.1. Laboratory Testing
- 5.2.2. Point-of-Care (POC) Testing
- 5.3. Market Analysis, Insights and Forecast - By Indication
- 5.3.1. Myocardial Infarction
- 5.3.2. Congestive Heart Failure
- 5.3.3. Acute Coronary Syndrome
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By End-User
- 5.4.1. Hospitals & Clinics
- 5.4.2. Diagnostic Laboratories
- 5.4.3. Homecare Settings & Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Troponin T
- 6.1.2. Troponin I
- 6.2. Market Analysis, Insights and Forecast - By Setting
- 6.2.1. Laboratory Testing
- 6.2.2. Point-of-Care (POC) Testing
- 6.3. Market Analysis, Insights and Forecast - By Indication
- 6.3.1. Myocardial Infarction
- 6.3.2. Congestive Heart Failure
- 6.3.3. Acute Coronary Syndrome
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast - By End-User
- 6.4.1. Hospitals & Clinics
- 6.4.2. Diagnostic Laboratories
- 6.4.3. Homecare Settings & Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Troponin T
- 7.1.2. Troponin I
- 7.2. Market Analysis, Insights and Forecast - By Setting
- 7.2.1. Laboratory Testing
- 7.2.2. Point-of-Care (POC) Testing
- 7.3. Market Analysis, Insights and Forecast - By Indication
- 7.3.1. Myocardial Infarction
- 7.3.2. Congestive Heart Failure
- 7.3.3. Acute Coronary Syndrome
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast - By End-User
- 7.4.1. Hospitals & Clinics
- 7.4.2. Diagnostic Laboratories
- 7.4.3. Homecare Settings & Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Rest of Europe
8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Troponin T
- 8.1.2. Troponin I
- 8.2. Market Analysis, Insights and Forecast - By Setting
- 8.2.1. Laboratory Testing
- 8.2.2. Point-of-Care (POC) Testing
- 8.3. Market Analysis, Insights and Forecast - By Indication
- 8.3.1. Myocardial Infarction
- 8.3.2. Congestive Heart Failure
- 8.3.3. Acute Coronary Syndrome
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast - By End-User
- 8.4.1. Hospitals & Clinics
- 8.4.2. Diagnostic Laboratories
- 8.4.3. Homecare Settings & Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. Rest of Asia Pacific
9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Troponin T
- 9.1.2. Troponin I
- 9.2. Market Analysis, Insights and Forecast - By Setting
- 9.2.1. Laboratory Testing
- 9.2.2. Point-of-Care (POC) Testing
- 9.3. Market Analysis, Insights and Forecast - By Indication
- 9.3.1. Myocardial Infarction
- 9.3.2. Congestive Heart Failure
- 9.3.3. Acute Coronary Syndrome
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast - By End-User
- 9.4.1. Hospitals & Clinics
- 9.4.2. Diagnostic Laboratories
- 9.4.3. Homecare Settings & Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Troponin T
- 10.1.2. Troponin I
- 10.2. Market Analysis, Insights and Forecast - By Setting
- 10.2.1. Laboratory Testing
- 10.2.2. Point-of-Care (POC) Testing
- 10.3. Market Analysis, Insights and Forecast - By Indication
- 10.3.1. Myocardial Infarction
- 10.3.2. Congestive Heart Failure
- 10.3.3. Acute Coronary Syndrome
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast - By End-User
- 10.4.1. Hospitals & Clinics
- 10.4.2. Diagnostic Laboratories
- 10.4.3. Homecare Settings & Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. bioMerieux SA
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Abbott
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. Siemens Healthineers AG
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Eurolyser Diagnostica GmbH
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. QuidelOrtho (Quidel Corporation)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. PerkinElmer Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. Beckman Coulter, Inc. (Danaher)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (Based on Availability)
- 11.2.9. RESPONSE BIOMEDICAL
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. financials (Based on Availability)
- 11.2.10. LifeSign LLC.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. financials (Based on Availability)
- 11.2.1. F. Hoffmann-La Roche Ltd.
List of Tables
- Table 1: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 3: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 4: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 5: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 7: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 8: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 9: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 10: North America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 12: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 13: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 14: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 15: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 17: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 18: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 19: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 20: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 22: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 23: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 24: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 25: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 27: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 28: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 29: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 30: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Cardiac Troponin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Cardiac Troponin Market Value Share (%), By Type, 2025 & 2034
- Figure 3: Global Cardiac Troponin Market Value Share (%), by Setting, 2025 & 2034
- Figure 4: Global Cardiac Troponin Market Value Share (%), by Indication, 2025 & 2034
- Figure 5: Global Cardiac Troponin Market Value Share (%), by End-User, 2025 & 2034
- Figure 6: Global Cardiac Troponin Market Value (USD billion), by Region, 2025 & 2034
- Figure 7: North America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 8: North America Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 9: North America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 10: North America Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 11: North America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 12: North America Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 13: North America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 14: North America Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 15: North America Cardiac Troponin Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Cardiac Troponin Market Value Share (%), By Country, 2025
- Figure 17: Europe Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 18: Europe Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 19: Europe Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 20: Europe Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 21: Europe Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 22: Europe Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 23: Europe Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 24: Europe Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 25: Europe Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 28: Asia Pacific Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 29: Asia Pacific Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 30: Asia Pacific Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 31: Asia Pacific Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 32: Asia Pacific Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 33: Asia Pacific Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 34: Asia Pacific Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 35: Asia Pacific Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 38: Latin America Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 39: Latin America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 40: Latin America Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 41: Latin America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 42: Latin America Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 43: Latin America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 44: Latin America Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 45: Latin America Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 48: Middle East & Africa Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 49: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 50: Middle East & Africa Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 51: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 52: Middle East & Africa Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 53: Middle East & Africa Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 54: Middle East & Africa Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 55: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034s
- Figure 56: Middle East & Africa Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Cardiac Troponin Market Share (%), By Company, 2025
